Adults with diabetes using an implantable 1-year continuous glucose monitoring sensor had a mean time in range of about 66% ...

The biggest names in cardiology tech gathered in New Orleans for the American College of Cardiology (ACC) Scientific Sessions ...

NEW ALBANY — Baptist Health Floyd recently completed its 500th Watchman procedure. The Watchman device is an alternative to ...

A new Watchman device at McLaren Port Huron offers eligible AFib patients an alternative to long‑term blood thinners to help ...

Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.

CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...

Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.

Today, March 30, 2026, investors send Boston Scientific shares lower as they dig deeper into the company's latest trial ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar ...

The study evaluated the company’s Watchman FLX device, designed to reduce stroke risk in patients with non valvular atrial ...

Boston Scientific (NYSE:BSX) shares fell 9% after the company’s CHAMPION-AF trial results for its Watchman heart implant failed to meet investor expectations, d ...

The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...